PT Merck Tbk MERK
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if MERK is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- 10.03
- Price/Sales
- 1.86
- Dividend Yield (Trailing)
- 8.02%
- Dividend Yield (Forward)
- 8.02%
- Total Yield
- 8.02%
Company Profile
PT Merck Tbk engages in the manufacture and sale of pharmaceutical products in Indonesia. The company operates in three segments: Biopharma, Consumer Health, and Others. The company offers pharmaceutical and biological prescription medicines to treat cancer, multiple sclerosis, infertility, growth disorders, and cardiovascular and metabolic diseases, as well as chronic diseases.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Value
- Total Number of Employees
- 390
- Website
- https://www.merck.co.id
Comparables
Valuation
|
Metric
|
MERK
|
INVA
|
AMLX
|
|---|---|---|---|
Price/Earnings (Normalized) | 10.03 | 9.26 | 1.72 |
Price/Book Value | 2.25 | 1.43 | 0.32 |
Price/Sales | 1.86 | 4.25 | 0.37 |
Price/Cash Flow | 8.77 | 7.96 | 1.83 |
Price/Earnings
MERK
INVA
AMLX
Financial Strength
|
Metric
|
MERK
|
INVA
|
AMLX
|
|---|---|---|---|
Quick Ratio | 2.63 | 7.28 | 5.01 |
Current Ratio | 5.74 | 9.03 | 5.66 |
Interest Coverage | 49.43 | 10.31 | — |
Quick Ratio
MERK
INVA
AMLX
Profitability
|
Metric
|
MERK
|
INVA
|
AMLX
|
|---|---|---|---|
Return on Assets (Normalized) | 18.35% | 14.79% | 18.55% |
Return on Equity (Normalized) | 23.41% | 29.29% | 21.48% |
Return on Invested Capital (Normalized) | 22.54% | 16.71% | 17.45% |
Return on Assets
MERK
INVA
AMLX
Drug Manufacturers - Specialty & Generic Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
ZTS
| Zoetis Inc Class A | Mqlplrlmn | Hzzt | $76.2 Bil | |
MKKGY
| Merck KGaA ADR | Vslkwlvxk | Jpdjbkc | $70.9 Bil | |
HLN
| Haleon PLC ADR | Rztcrlrl | Jspd | $37.8 Bil | |
VTRS
| Viatris Inc | Dmyynlyn | Msw | $14.0 Bil | |
RDY
| Dr Reddy's Laboratories Ltd ADR | Sgqttzbz | Byw | $12.7 Bil | |
CTLT
| Catalent Inc | Bktsrwfs | Pccnvry | $10.2 Bil | |
PRGO
| Perrigo Co PLC | Tpjltpbv | Fgb | $4.4 Bil | |
CURLF
| Curaleaf Holdings Inc | Zzgnqdbsz | Xzgf | $4.1 Bil | |
PBH
| Prestige Consumer Healthcare Inc | Fsxbbfhjm | Grbfwqr | $3.5 Bil | |
GTBIF
| Green Thumb Industries Inc | Kjcrdykv | Kbrj | $3.1 Bil |